Key result
Thrombolytic therapy successfully treated a rare case of bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome 15 months after valve replacement.
Case Report (n=1)
Thrombolytic therapy was successfully used to treat a rare case of bioprosthetic mitral valve thrombosis in a patient with antiphospholipid antibody syndrome.
May support thrombolysis in rare bioprosthetic valve thrombosis with APS; hypothesis-generating and should not yet change practice.
The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly limited. We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months after valve replacement, and successfully treated with thrombolytic therapy.
No takes yet. Share an insight, caveat, or question.
Chamsi‐Pasha et al. (2014) conducted a case report in Antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis (n=1). Thrombolytic therapy was evaluated on Successful treatment of bioprosthetic mitral valve thrombosis. Thrombolytic therapy successfully treated a rare case of bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome 15 months after valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: